english.prescrire.org > Spotlight > 100 most recent > In the January issue of Prescrire International: Strontium still authorised despite an unfavourable opinion of the European pharmacovigilance committee

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

In the January issue of Prescrire International: Strontium still authorised despite an unfavourable opinion of the European pharmacovigilance committee

FREE DOWNLOAD Strontium ranelate (Protelos° - Servier), a drug authorised in the European Union for severe osteoporosis, has at best only modest efficacy in secondary prevention of vertebral fractures. In stark contrast, it carries a risk of disproportionate adverse effects.
Full text available for free download.

Summary

  • In 2014 the indications of strontium ranelate were further restricted in the European Union.
     
  • The French pharmacoeconomic committee has finally judged strontium ranelate to have “insufficient medical benefit”.
     
  • In practice, it is best to follow the advice of the European Pharmacovigilance Risk Assessment Committee (PRAC): this drug should have been discarded. long ago.
     

 Full text available for free download.

 ©Prescrire 1 January 2015

"Strontium still authorised despite an unfavourable opinion of the European pharmacovigilance committee" Prescrire Int 2014; 24 (156): 15. (Pdf, free)

 
Download the full review
Pdf, free